Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
